PHC Holdings Corporation (PHCCF)
OTCMKTS · Delayed Price · Currency is USD
5.98
0.00 (0.00%)
Jul 18, 2025, 9:30 AM EDT
PHC Holdings Revenue
In the fiscal year ending March 31, 2025, PHC Holdings had annual revenue of 361.59B JPY with 2.17% growth. PHC Holdings had revenue of 94.68B in the quarter ending March 31, 2025, a decrease of -2.61%.
Revenue
361.59B JPY
Revenue Growth
+2.17%
P/S Ratio
0.33
Revenue / Employee
39.99M JPY
Employees
9,041
Market Cap
785.25M USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 361.59B | 7.69B | 2.17% |
| Mar 31, 2024 | 353.90B | -2.53B | -0.71% |
| Mar 31, 2023 | 356.43B | 15.98B | 4.69% |
| Mar 31, 2022 | 340.45B | 34.38B | 11.23% |
| Mar 31, 2021 | 306.07B | 33.43B | 12.26% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo, Inc. | 1.73B |
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Elite Pharmaceuticals | 84.04M |
| Glass House Brands | 215.62M |
| Northwest Biotherapeutics | 1.47M |
| American Oncology Network | 1.76B |
| Silence Therapeutics | 27.70M |